To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors
ECOG performance status of 0 to 1.
Life expectancy of more than 3 months.
At least one measurable lesion exists.(RECIST 1.1)
Histologically or cytologic confirmed HER2 positive metastatic solid tumor which failed prior standard treatment or have no standard treatment.
Subjects who have received the prescribed treatment at the prescribed time prior to first dosing.
Known active infection within 2 weeks prior to baseline.
Subjects with third space fluid that can not be controled.
Subjects with uncontrolled or severe cardiovascular disease.